Evaluation of Hereditary Cancer Educational Videos
Recruiting
- Conditions
- Hereditary Cancer
- Interventions
- Behavioral: Survey StudyBehavioral: Interview Study
- First Posted Date
- 2023-12-06
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 74
- Registration Number
- NCT06157801
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
A Pilot Study for Pupillary Assessment to Predict CAR-T Related Neurotoxicity
Recruiting
- Conditions
- Neurotoxicity
- First Posted Date
- 2023-11-22
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 100
- Registration Number
- NCT06144151
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination with the PARP Inhibitor Olaparib in Patients with KRAS G12C Mutated Advanced Solid Tumors, with a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers
Phase 1
Recruiting
- Conditions
- Advanced Solid TumorNon-small Cell Lung Cancers
- Interventions
- First Posted Date
- 2023-11-14
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 52
- Registration Number
- NCT06130254
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Digital Art Activity to Enhance Self-Disclosure and the Detection of Psycho-social Distress in Adult Cancer Patients
Recruiting
- Conditions
- Cancer
- Interventions
- Behavioral: Digital Art Activity
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT06127121
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Surveillance MRI Registry for Patients Who Had Breast Cancer With Dense Breast Tissue
Recruiting
- Conditions
- Breast Cancer
- Interventions
- Behavioral: Questionnaire/Interview
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 1000
- Registration Number
- NCT06127797
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Exploring the Benefit of Neuromodulation in Treating Chemo-induced Peripheral Neuropathy Using Peripheral Neuropathy Markers (Meissner's Corpuscles and Epidermal Nerve Fiber Density) and Sensory Testing (Quantitative Sensory and Gait Testing): A Single Center Feasibility Study
Not Applicable
Recruiting
- Conditions
- Neuropathy;Peripheral
- Interventions
- Device: Abbott® DRG / Abbott®/Medtronic® SCSOther: Control Group
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT06121232
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Phase 1B/2A Trial of Combination of ASTX727 With ASTX029 in Acute Myeloid Leukemia
Phase 1
Suspended
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Drug: ASTX727Drug: ASTX029-01
- First Posted Date
- 2023-11-02
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 42
- Registration Number
- NCT06113289
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)
- First Posted Date
- 2023-11-02
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT06113302
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Prevención en Sus Manos: Feasibility of a Novel Community-Based Strategy to Improve Access to Cervical Cancer Screening
Not Applicable
Recruiting
- Conditions
- HPV
- Interventions
- Behavioral: PRECEDE-PROCEED
- First Posted Date
- 2023-10-31
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 920
- Registration Number
- NCT06109870
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸University of Texas at Austin, Austin, Texas, United States
Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma
- First Posted Date
- 2023-10-30
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 36
- Registration Number
- NCT06108232
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath